Search

Displaying results 4571 - 4580 of 10000 in total
  1. Drug

    Sulfamethizole

    go.drugbank.com/drugs/DB00576
    ApprovedVet approved

    A sulfathiazole antibacterial agent.

  2. Drug

    Proxalutamide

    go.drugbank.com/drugs/DB16065
    Investigational

    Proxalutamide is under investigation in clinical trial NCT03899467 (The Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer).

  3. Drug

    Eosin

    go.drugbank.com/drugs/DB13706
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Tyrosol

    go.drugbank.com/drugs/DB16855
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Linsitinib

    go.drugbank.com/drugs/DB06075
    Investigational

    IGF-1R inhibitor OSI-906 selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. … An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity.

  6. Drug

    Sulfametopyrazine

    go.drugbank.com/drugs/DB00664
    ApprovedWithdrawn

    Long-acting plasma-bound sulfonamide used for respiratory and urinary tract infections and also for malaria.

  7. Drug

    Nizofenone

    go.drugbank.com/drugs/DB13546
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Acriflavine

    go.drugbank.com/drugs/DB13373
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Pegdinetanib

    go.drugbank.com/drugs/DB05931
    Investigational

    CT-322 is a proprietary Adnectin(TM) protein therapeutic that, in preclinical studies, specifically binds to vascular endothelial growth factor receptor 2 (VEGFR-2), which regulates the primary tumor angiogenesis

  10. Drug

    ALGRX 1207

    go.drugbank.com/drugs/DB06482
    Experimental

    ALGRX 1207 entered clinical trials for cutaneous neuropathic pain, such as chemotherapy-induced neuropathy, in 2006. It was being developed by Anesiva, but trials have halted. … ALGRX 1207 is a topical local anesthetic that acts by binding to the fast sodium channel.